Company

Triveni Bio, Inc.

Triveni Bio develops functional antibodies using genetic insights to treat inflammatory and immunological disorders.

About

Triveni Bio develops functional antibodies using a genetics-informed precision medicine approach for inflammatory and immunological disorders. Its programs include TRIV-509 for atopic dermatitis and other skin barrier diseases. Founded in 2019 in Massachusetts, the company formed through the merger of Amagma Therapeutics and Modify Therapeutics. In June 2026, it raised USD 65 million in Series C funding co-led by Ascenta Capital and Janus Henderson Investors, with other participating investors including Bread & Butter Ventures, Victorum Capital, Gray Ventures, Circadian Ventures, Allied Venture Partners, High Street Equity Partners, and Deep Track Capital.

3Funding rounds

18Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in